Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 19/20 | 1.00 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.56 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.56 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16650720 | 1.00 | BRD4 (1.00) | BRD4BRD9BRD7BRDT | |
| Hydrochloric Acid SCHEMBL29848853 | 0.99 | BRD4 (0.97) | BRD4BRD9BRD7BRDT | |
| Hydrochloric Acid SCHEMBL16651302 | 0.99 | BRD4 (0.97) | BRD4BRD9BRD7BRDT | |
| SCHEMBL19857684 | 0.84 | BRD4 (0.72) | BRD4BRD9BRD7BRDT | |
| SCHEMBL29613205 | 0.84 | BRD4 (0.72) | BRD4BRD9BRD7BRDT | |
| SCHEMBL29848755 | 0.81 | BRD4 (1.00) | BRD4BRD9BRD7 | |
| SCHEMBL16651105 | 0.81 | BRD4 (1.00) | BRD4BRD9BRD7 | |
| Hydrochloric Acid SCHEMBL16651039 | 0.80 | BRD4 (0.97) | BRD4BRD9BRD7 | |
| Hydrochloric Acid SCHEMBL29848868 | 0.80 | BRD4 (0.97) | BRD4BRD9BRD7 | |
| SCHEMBL15893960 | 0.79 | BRD4 (0.74) | BRD4BRD9BRD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11884680-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| EP-4134364-A2 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| EP-3640241-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2022-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885BRD9 19/4885BRD7 14/4885 |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885BRD9 19/4885BRD7 14/4885 |
| US-11884680-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | BRD4 5/4885BRD9 19/4885BRD7 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.